. 2024 Feb 9;42(12):1344–1349. doi: 10.1200/JCO.23.01428

TABLE 2.

Subset Analyses: ABC Protocols

IDFS End Point
Characteristic	Patients		Events		HR (95% CI)	P	Interaction P Value
Characteristic	TaxAC	TC	TaxAC	TC	HR (95% CI)	P	Interaction P Value
Protocol^a
USOR 06-090	642	645	97	140	1.39 (1.07 to 1.80)	.01
B-46-I/07132	522	529	75	88	1.21 (0.89 to 1.65)	.23	.11
B-49	915	928	170	161	0.96 (0.78 to 1.20)	.74
Hormone receptor^a
Negative	657	647	114	139	1.30 (1.02 to 1.67)	.04	.21
Positive	1,422	1,455	228	250	1.06 (0.89 to 1.27)	.50
Positive nodes^a
0	824	866	120	141	1.10 (0.86 to 1.40)	.45
1-3	934	914	130	145	1.16 (0.91 to 1.47)	.23	.82
4+	321	322	92	103	1.14 (0.86 to 1.51)	.36
Race^b
White	1,747	1,803	280	331	1.17 (1.0 to 1.37)	.06	.58
Black	223	238	43	50	1.09 (0.71 to 1.68)	.69
Histologic grade^b
Low/intermediate	977	994	138	153	1.08 (0.86 to 1.36)	.51	.71
High	1,062	1,073	199	230	1.15 (0.95 to 1.39)	.15
Overall	2,079	2,102	342	389	1.14 (0.99 to 1.32)	.08
RFI End Point
	Patients		Events
Characteristic	TaxAC	TC	TaxAC	TC	HR (95% CI)	P	Interaction P Value
Protocol^a
USOR 06-090	642	645	61	111	1.76 (1.29 to 2.40)	.0003
B-46-I/07132	522	529	50	68	1.40 (0.97 to 2.03)	.07	.13
B-49	915	928	105	116	1.15 (0.88 to 1.49)	.32
Hormone receptor^a
Negative	657	647	62	107	1.90 (1.39 to 2.61)	<.0001	.02
Positive	1,422	1,455	154	188	1.19 (0.96 to 1.47)	.11
Positive nodes^a
0	824	866	64	104	1.52 (1.11 to 2.07)	.008
1-3	934	914	84	105	1.30 (0.97 to 1.73)	.08	.41
4+	321	322	68	86	1.29 (0.94 to 1.77)	.12
Race^b
White	1,747	1,803	177	249	1.40 (1.15 to 1.70)	.0007	.87
Black	223	238	27	40	1.52 (0.90 to 2.54)	.11
Histologic grade^b
Low/intermediate	977	994	86	110	1.23 (0.93 to 1.64)	.15	.41
High	1,062	1,073	127	181	1.44 (1.15 to 1.82)	.002
Overall	2,079	2,102	216	295	1.38 (1.16 to 1.65)	.0003
OS End Point
	Patients		Events
Characteristic	TaxAC	TC	TaxAC	TC	HR (95% CI)	P	Interaction P Value
Protocol^a
USOR 06-090	642	645	71	89	1.18 (0.87 to 1.62)	.29
B-46-I/07132	522	529	45	58	1.27 (0.86 to 1.88)	.23	.21
B-49	915	928	105	87	0.85 (0.64 to 1.13)	.27
Hormone receptor^a
Negative	657	647	75	94	1.30 (0.96 to 1.77)	.09	.10
Positive	1,422	1,455	146	140	0.92 (0.73 to 1.16)	.49
Positive nodes^a
0	824	866	76	84	1.01 (0.74 to 1.38)	.93
1-3	934	914	77	80	1.08 (0.79 to 1.48)	.64	.92
4+	321	322	68	70	1.02 (0.73 to 1.43)	.90
Race^b
White	1,747	1,803	181	196	1.06 (0.86 to 1.30)	.58	.94
Black	223	238	28	34	1.12 (0.66 to 1.90)	.67
Histologic grade^b
Low/intermediate	977	994	78	80	0.98 (0.72 to 1.35)	.91	.84
High	1,062	1,073	141	150	1.03 (0.81 to 1.30)	.82
Overall	2,079	2,102	221	234	1.05 (0.87 to 1.26)	.64

Abbreviations: ABC, anthracyclines in early breast cancer; HR, hazard ratio; IDFS, invasive disease-free survival; OS, overall survival; RFI, recurrence-free interval; TaxAC, docetaxel or paclitaxel with cyclophosphamide and doxorubicin; TC, docetaxel with cyclophosphamide.

^aPrespecified subset analysis.

^bExploratory subset analysis.